Form 4: Akero Therapeutics Chief Scientific Officer Acquires Shares Through Employee Stock Purchase Plan

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, acquired 890 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), acquired 890 shares of the company's common stock.
• The transaction occurred on June 30, 2025, and was reported on July 2, 2025.
• The shares were purchased at a price of $23.868 per share.
• This acquisition was made pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price of $23.868 represents 85% of the closing price of Akero Therapeutics' common stock on January 2, 2025.
• Following this transaction, Timothy Rolph beneficially owns a total of 167,124 shares of common stock.
• The transaction is exempt under SEC Rules 16b-3(c) and 16b-3(d).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While an Employee Stock Purchase Plan acquisition is a routine transaction and not as strong a signal as an open market purchase, it still represents an increase in insider ownership and alignment of interests, which is generally viewed favorably by investors.

Positives

• The acquisition of shares by a Chief Scientific Officer demonstrates continued alignment of management's interests with those of shareholders.
• Participation in the Employee Stock Purchase Plan indicates confidence in the company's long-term prospects by key personnel.

Future Outlook

This Form 4 filing is a historical report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction common in publicly traded companies, where executives and employees acquire shares through company-sponsored plans like an Employee Stock Purchase Plan. It reflects an individual's participation in a standard employee benefit rather than a strategic market move.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a common benefit offered by companies across various industries, including biotechnology, to allow employees to purchase company stock, often at a discount.
• The 15% discount (purchase at 85% of market price) offered by Akero Therapeutics' ESPP is a standard discount percentage observed in many corporate ESPPs.

Stakeholder Impact

• Shareholders: The increase in insider ownership by a key executive can be viewed as a positive signal, reinforcing confidence in the company's future.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, insider trading, stock purchase, employee stock purchase plan, Timothy Rolph, Chief Scientific Officer